SpringerLink
Log in

Cerebrovascular Disease and Chronic Kidney Disease

  • Chapter
  • First Online:
Management of Chronic Kidney Disease

  • 407 Accesses

Abstract

Chronic kidney disease (CKD) is a rapidly rising global health burden and a major risk factor for both ischaemic and haemorrhagic stroke as well as subclinical cerebrovascular disease. Several pathophysiological mechanisms have been proposed to underlie the kidney–brain axis including shared traditional risk factors such as hypertension and diabetes mellitus, uraemia-related non-traditional risk factors such as chronic inflammation and abnormal mineral-bone metabolism, and dialysis-specific factors such as cerebral hypoperfusion and intradialytic cerebral ischaemia. CKD frequently complicates routine stroke risk prediction, diagnosis, management, and prevention. It is also associated with greater stroke severity, worse functional outcomes and higher stroke mortality. Here we present an evidence-based summary of the epidemiology, pathophysiology, diagnosis, prevention, and treatment of cerebrovascular disease in CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 160.49
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
EUR 213.99
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392:2052–90.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.

    Article  PubMed  Google Scholar 

  3. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.

    Article  PubMed  Google Scholar 

  4. Kelly D, Rothwell PM. Disentangling the multiple links between renal dysfunction and cerebrovascular disease. J Neurol Neurosurg Psychiatry. 2020;91:88–97.

    Article  PubMed  Google Scholar 

  5. Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014;13:823–33.

    Article  PubMed  Google Scholar 

  6. Doehner W, Ural D, Haeusler KG, Čelutkienė J, Bestetti R, Cavusoglu Y, et al. Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the study group on heart and brain interaction of the heart failure association. Eur J Heart Fail. 2018;20:199–215.

    Article  PubMed  Google Scholar 

  7. Findlay M, MacIsaac R, MacLeod MJ, Metcalfe W, Traynor JP, Dawson J, et al. Renal replacement modality and stroke risk in end-stage renal disease—a national registry study. Nephrol Dial Transplant. 2018;33:1564–71.

    CAS  PubMed  Google Scholar 

  8. System USRD. Usrds 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States; 2009.

    Google Scholar 

  9. Hallan SIRE, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol. 2009;20:1069–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lee M, Saver JL, Chang KH, Ovbiagele B. Level of albuminuria and risk of stroke: systematic review and meta-analysis. Cerebrovasc Dis. 2010;30:464–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kelly DM, Rothwell PM. Does chronic kidney disease predict stroke risk independent of blood pressure?: a systematic review and meta-regression. Stroke. 2019;50:3085–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ghoshal S, Freedman BI. Mechanisms of stroke in patients with chronic kidney disease. Am J Nephrol. 2019;50:229–39.

    Article  PubMed  Google Scholar 

  13. Mace-Brickman T, Eddeen AB, Carrero JJ, Mark PB, Molnar AO, Lam NN, et al. The risk of stroke and stroke type in patients with atrial fibrillation and chronic kidney disease. Can J Kidney Health Dis. 2019;6:2054358119892372.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Massicotte-Azarniouch DKJ, Carrero JJ, Lam NN, Molnar AO, Zimmerman D, McCallum MK, Garg AX, Sood MM. Incident atrial fibrillation and the risk of congestive heart failure, myocardial infarction, end-stage kidney disease, and mortality among patients with a decreased estimated GFR. Am J Kidney Dis. 2018;71:191–9.

    Article  PubMed  Google Scholar 

  15. Murray AM, Seliger S, Lakshminarayan K, Herzog CA, Solid CA. Incidence of stroke before and after dialysis initiation in older patients. J Am Soc Nephrol. 2013;24:1166–73.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med. 2011;365:1099–107.

    Article  CAS  PubMed  Google Scholar 

  17. Ovbiagele B, Schwamm LH, Smith EE, Grau-Sepulveda MV, Saver JL, Bhatt DL, et al. Hospitalized hemorrhagic stroke patients with renal insufficiency: clinical characteristics, care patterns, and outcomes. J Stroke Cerebrovasc Dis. 2014;23:2265–73.

    Article  PubMed  Google Scholar 

  18. Kumai Y, Kamouchi M, Hata J, Ago T, Kitayama J, Nakane H, et al. Proteinuria and clinical outcomes after ischemic stroke. Neurology. 2012;78:1909–15.

    Article  CAS  PubMed  Google Scholar 

  19. Kumar DRHE, Glurich I, Mazza JJ, Yale SH. Virchow’s contribution to the understanding of thrombosis and cellular biology. Clin Med Res. 2010;8:168–72.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006;19:317–22.

    Article  PubMed  Google Scholar 

  21. Freeman WD, Wadei HM. A brain–kidney connection: the delicate interplay of brain and kidney physiology. Neurocrit Care. 2015;22:173–5.

    Article  PubMed  Google Scholar 

  22. Ito S, Nagasawa T, Abe M, Mori T. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res. 2009;32:115–21.

    Article  PubMed  Google Scholar 

  23. Bernbaum M, Menon BK, Fick G, Smith EE, Goyal M, Frayne R, et al. Reduced blood flow in normal white matter predicts development of leukoaraiosis. J Cereb Blood Flow Metab. 2015;35:1610–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The steno hypothesis. Diabetologia. 1989;32:219–26.

    Article  CAS  PubMed  Google Scholar 

  25. Apostolov EO, Ok E, Burns S, Nawaz S, Savenka A, Shah S, et al. Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophages. J Atheroscler Thromb. 2013;20:878–92.

    Article  PubMed  Google Scholar 

  26. Lau WL, Ix JH. Clinical detection, risk factors, and cardiovascular consequences of medial arterial calcification: a pattern of vascular injury associated with aberrant mineral metabolism. Semin Nephrol. 2013;33:93–105.

    Article  CAS  PubMed  Google Scholar 

  27. MacEwen C, Sutherland S, Daly J, Pugh C, Tarassenko L. Relationship between hypotension and cerebral ischemia during hemodialysis. J Am Soc Nephrol. 2017;28:2511–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Chesterton LJ, Sigrist MK, Bennett T, Taal MW, McIntyre CW. Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness. Nephrol Dial Transplant. 2005;20:1140–7.

    Article  PubMed  Google Scholar 

  29. Saver JL. Time is brain—quantified. Stroke. 2006;37:263–6.

    Article  PubMed  Google Scholar 

  30. Newsome BB, Warnock DG, Kiefe CI, Weissman NW, Houston TK, Centor RM, et al. Delay in time to receipt of thrombolytic medication among medicare patients with kidney disease. Am J Kidney Dis. 2005;46:595–602.

    Article  CAS  PubMed  Google Scholar 

  31. Brinjikji W, Demchuk AM, Murad MH, Rabinstein AA, McDonald RJ, McDonald JS, et al. Neurons over nephrons: systematic review and meta-analysis of contrast-induced nephropathy in patients with acute stroke. Stroke. 2017;48:1862–8.

    Article  PubMed  Google Scholar 

  32. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168–75.

    Article  PubMed  Google Scholar 

  33. Kelly DM, Ademi Z, Doehner W, Lip GYH, Mark P, Toyoda K, et al. Chronic kidney disease and cerebrovascular disease: consensus and guidance from a KDIGO controversies conference. Stroke. 2021;52:e328–46.

    Article  CAS  PubMed  Google Scholar 

  34. Ovbiagele B, Schwamm LH, Smith EE, Grau-Sepulveda MV, Saver JL, Bhatt DL, et al. Patterns of care quality and prognosis among hospitalized ischemic stroke patients with chronic kidney disease. J Am Heart Assoc. 2014;3:e000905.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Findlay MD, Dawson J, MacIsaac R, Jardine AG, MacLeod MJ, Metcalfe W, et al. Inequality in care and differences in outcome following stroke in people with ESRD. Kidney Int Rep. 2018;3:1064–76.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Molnar AO, Bota SE, Garg AX, Harel Z, Lam N, McArthur E, et al. The risk of major hemorrhage with CKD. J Am Soc Nephrol. 2016;27:2825–32.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380:1795–803.

    Article  PubMed  Google Scholar 

  39. Jung JMKH, Ahn H, Ahn IM, Do Y, Choi JY, Seo WK, Oh K, Cho KH, Yu S. Chronic kidney disease and intravenous thrombolysis in acute stroke: a systematic review and meta-analysis. J Neurol Sci. 2015;358:345–50.

    Article  PubMed  Google Scholar 

  40. Carr SJ, Wang X, Olavarria VV, Lavados PM, Rodriguez JA, Kim JS, et al. Influence of renal impairment on outcome for thrombolysis-treated acute ischemic stroke: enchanted (enhanced control of hypertension and thrombolysis stroke study) post hoc analysis. Stroke. 2017;48:2605–9.

    Article  PubMed  Google Scholar 

  41. Tariq N, Adil MM, Saeed F, Chaudhry SA, Qureshi AI. Outcomes of thrombolytic treatment for acute ischemic stroke in dialysis-dependent patients in the United States. J Stroke Cerebrovasc Dis. 2013;22:e354–9.

    Article  PubMed  Google Scholar 

  42. Saeed F, Adil MM, Piracha BH, Qureshi AI. Outcomes of endovascular versus intravenous thrombolytic treatment for acute ischemic stroke in dialysis patients. Int J Artif Organs. 2014;37:727–33.

    Article  PubMed  Google Scholar 

  43. Laible M, Jenetzky E, Mohlenbruch MA, Neuberger U, Bendszus M, Ringleb PA, et al. Renal impairment is associated with intracerebral hemorrhage after mechanical thrombectomy in vertebrobasilar stroke. Cerebrovasc Dis. 2019;47:48–56.

    Article  PubMed  Google Scholar 

  44. Lindsberg PJ, Mattle HP. Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke. 2006;37:922–8.

    Article  PubMed  Google Scholar 

  45. Stroke Unit Trialists Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ. 1997;314:1151–9.

    Article  Google Scholar 

  46. Winney RJ, Kean DM, Best JJ, Smith MA. Changes in brain water with haemodialysis. Lancet. 1986;2:1107–8.

    Article  CAS  PubMed  Google Scholar 

  47. Galons JP, Trouard T, Gmitro AF, Lien YH. Hemodialysis increases apparent diffusion coefficient of brain water in nephrectomized rats measured by isotropic diffusion-weighted magnetic resonance imaging. J Clin Invest. 1996;98:750–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Polinder-Bos HA, Garcia DV, Kuipers J, Elting JWJ, Aries MJH, Krijnen WP, et al. Hemodialysis induces an acute decline in cerebral blood flow in elderly patients. J Am Soc Nephrol. 2018;29:1317–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kumar A, Cage A, Dhar R. Dialysis-induced worsening of cerebral edema in intracranial hemorrhage: a case series and clinical perspective. Neurocrit Care. 2015;22:283–7.

    Article  PubMed  Google Scholar 

  50. Davenport A. Practical guidance for dialyzing a hemodialysis patient following acute brain injury. Hemodial Int. 2008;12:307–12.

    Article  PubMed  Google Scholar 

  51. Davenport A. Changing the hemodialysis prescription for hemodialysis patients with subdural and intracranial hemorrhage. Hemodial Int. 2013;17(Suppl 1):S22–7.

    PubMed  Google Scholar 

  52. Davenport A, Will EJ, Davison AM. Early changes in intracranial pressure during haemofiltration treatment in patients with grade 4 hepatic encephalopathy and acute oliguric renal failure. Nephrol Dial Transplant. 1990;5:192–8.

    Article  CAS  PubMed  Google Scholar 

  53. Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTS in critically ill patients with Aki. Clin J Am Soc Nephrol. 2014;9:2173–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Eldehni MT, Odudu A, McIntyre CW. Randomized clinical trial of dialysate cooling and effects on brain white matter. J Am Soc Nephrol. 2015;26:957–65.

    Article  CAS  PubMed  Google Scholar 

  55. Committee MW. Personalised cooler dialysate for patients receiving maintenance haemodialysis (mytemp): a pragmatic, cluster-randomised trial. Lancet. 2022;400:1693–703.

    Article  Google Scholar 

  56. Krane NK. Intracranial pressure measurement in a patient undergoing hemodialysis and peritoneal dialysis. Am J Kidney Dis. 1989;13:336–9.

    Article  CAS  PubMed  Google Scholar 

  57. Wanner C, Tonelli M. Kdigo clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303–9.

    Article  CAS  PubMed  Google Scholar 

  58. Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant. 2013;28(Suppl 4):iv82–98.

    Article  PubMed  Google Scholar 

  59. Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2014;64:383–93.

    Article  PubMed  Google Scholar 

  60. Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, et al. Cigarette smoking increases the risk of albuminuria among subjects with type i diabetes. JAMA. 1991;265:614–7.

    Article  CAS  PubMed  Google Scholar 

  61. Conditions tCCfC. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. Royal College of Physicians; 2008.

    Google Scholar 

  62. Major RW, Oozeerally I, Dawson S, Riddleston H, Gray LJ, Brunskill NJ. Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: a meta-analysis. Atherosclerosis. 2016;251:177–82.

    Article  CAS  PubMed  Google Scholar 

  63. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013;(2):CD008834.

    Google Scholar 

  64. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet. 2016;388:365–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.

    Article  PubMed  Google Scholar 

  66. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–30.

    Article  PubMed  Google Scholar 

  67. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    Article  PubMed  Google Scholar 

  68. Buckley LF, Rybak E, Aldemerdash A, Cheng JW, Fanikos J. Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. Clin Cardiol. 2017;40:46–52.

    Article  PubMed  Google Scholar 

  69. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.

    Article  CAS  PubMed  Google Scholar 

  70. Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. 2016;149:951–9.

    Article  PubMed  Google Scholar 

  71. Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, et al. Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2019;171:181.

    Article  PubMed  Google Scholar 

  72. Glund S, Stangier J, van Ryn J, Schmohl M, Moschetti V, Haazen W, et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study. Clin Pharmacokinet. 2017;56:41–54.

    Article  CAS  PubMed  Google Scholar 

  73. Harel Z, Chertow GM, Shah PS, Harel S, Dorian P, Yan AT, et al. Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis. Can J Cardiol. 2017;33:737–46.

    Article  PubMed  Google Scholar 

  74. Bonde AN, Lip GYH, Kamper AL, Staerk L, Torp-Pedersen C, Gislason G, et al. Renal function, time in therapeutic range and outcomes in warfarin-treated atrial fibrillation patients: a retrospective analysis of nationwide registries. Thromb Haemost. 2017;117:2291–9.

    Article  PubMed  Google Scholar 

  75. Poterucha TJ, Goldhaber SZ. Warfarin and vascular calcification. Am J Med. 2016;129(635):e631–4.

    Google Scholar 

  76. De Vriese AS, Caluwe R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, et al. Multicenter randomized controlled trial of vitamin k antagonist replacement by rivaroxaban with or without vitamin k2 in hemodialysis patients with atrial fibrillation: the Valkyrie study. J Am Soc Nephrol. 2020;31:186–96.

    Article  PubMed  Google Scholar 

  77. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138:1519–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Pokorney S. Renal hemodialysis patients allocated apixaban versus warfarin in atrial fibrillation—RENAL-AF. American Heart Association Annual Scientific Sessions (AHA 2019); 2019.

    Google Scholar 

  79. Okumura K, Lip GYH, Akao M, Tanizawa K, Fukuzawa M, Abe K, et al. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: rationale and design of the Eldercare-AF study. Am Heart J. 2017;194:99–106.

    Article  CAS  PubMed  Google Scholar 

  80. Kefer J, Tzikas A, Freixa X, Shakir S, Gafoor S, Nielsen-Kudsk JE, et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol. 2016;207:335–40.

    Article  PubMed  Google Scholar 

  81. Fox KAA, Eikelboom JW, Shestakovska O, Connolly SJ, Metsarinne KP, Yusuf S. Rivaroxaban plus aspirin in patients with vascular disease and renal dysfunction: from the compass trial. J Am Coll Cardiol. 2019;73:2243–50.

    Article  CAS  PubMed  Google Scholar 

  82. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering ldl cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263–75.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;(5):CD007784.

    Google Scholar 

  85. Yan YL, Qiu B, Wang J, Deng SB, Wu L, **g XD, et al. High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open. 2015;5:e006886.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70:1785–822.

    Article  PubMed  Google Scholar 

  87. Kassimatis TI, Goldsmith DJ. Statins in chronic kidney disease and kidney transplantation. Pharmacol Res. 2014;88:62–73.

    Article  CAS  PubMed  Google Scholar 

  88. Chen Y, Ku H, Zhao L, Wheeler DC, Li LC, Li Q, et al. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-coa reductase feedback regulation. Arterioscler Thromb Vasc Biol. 2014;34:365–76.

    Article  CAS  PubMed  Google Scholar 

  89. Chen Z, Qureshi AR, Parini P, Hurt-Camejo E, Ripsweden J, Brismar TB, et al. Does statins promote vascular calcification in chronic kidney disease? Eur J Clin Invest. 2017;47:137–48.

    Article  CAS  PubMed  Google Scholar 

  90. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.

    Article  CAS  PubMed  Google Scholar 

  91. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.

    Article  CAS  PubMed  Google Scholar 

  92. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1–S87.

    Google Scholar 

  93. Li Y, Liang M, Jiang C, Wang G, Li J, Zhang Y, et al. Impact of achieved blood pressure on renal function decline and first stroke in hypertensive patients with chronic kidney disease. Nephrol Dial Transplant. 2018;33:409–17.

    Article  CAS  PubMed  Google Scholar 

  94. Cheung AK, Chang TI, Cushman WC, Furth SL, Ix JH, Pecoits-Filho R, et al. Blood pressure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95:1027–36.

    Article  PubMed  Google Scholar 

  95. Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the progress study. J Am Soc Nephrol. 2007;18:2766–72.

    Article  PubMed  Google Scholar 

  96. Peralta CA, McClure LA, Scherzer R, Odden MC, White CL, Shlipak M, et al. Effect of intensive versus usual blood pressure control on kidney function among individuals with prior lacunar stroke: a post hoc analysis of the secondary prevention of small subcortical strokes (sps3) randomized trial. Circulation. 2016;133:584–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Park J, Rhee CM, Sim JJ, Kim YL, Ricks J, Streja E, et al. A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival. Kidney Int. 2013;84:795–802.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Mathew A, Eliasziw M, Devereaux PJ, Merino JG, Barnett HJ, Garg AX. Carotid endarterectomy benefits patients with CKD and symptomatic high-grade stenosis. J Am Soc Nephrol. 2010;21:145–52.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Klarin D, Lancaster RT, Ergul E, Bertges D, Goodney P, Schermerhorn ML, et al. Perioperative and long-term impact of chronic kidney disease on carotid artery interventions. J Vasc Surg. 2016;64:1295–302.

    Article  PubMed  Google Scholar 

  100. Fallon JM, Goodney PP, Stone DH, Patel VI, Nolan BW, Kalish JA, et al. Outcomes of lower extremity revascularization among the hemodialysis-dependent. J Vasc Surg. 2015;62:1183–1191.e1181.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Ricotta JJ, Aburahma A, Ascher E, Eskandari M, Faries P, Lal BK. Updated society for vascular surgery guidelines for management of extracranial carotid disease. J Vasc Surg. 2011;54:e1–31.

    Article  PubMed  Google Scholar 

  102. Cooper M, Arhuidese IJ, Obeid T, Hicks CW, Canner J, Malas MB. Perioperative and long-term outcomes after carotid endarterectomy in hemodialysis patients. JAMA Surg. 2016;151:947–52.

    Article  PubMed  Google Scholar 

  103. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

    Article  CAS  PubMed  Google Scholar 

  104. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

    Article  CAS  PubMed  Google Scholar 

  105. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295.

    Article  CAS  PubMed  Google Scholar 

  106. Zhou Z, Lindley RI, Radholm K, Jenkins B, Watson J, Perkovic V, et al. Canagliflozin and stroke in type 2 diabetes mellitus. Stroke. 2019;50:396–404.

    Article  CAS  PubMed  Google Scholar 

  107. Guo M, Ding J, Li J, Wang J, Zhang T, Liu C, et al. Sglt2 inhibitors and risk of stroke in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20:1977–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Tallaght University Hospital, Dublin, Ireland

    Dearbhail Ni Cathain

  2. Nuffield Department of Clinical Neurosciences, Wolfson Centre for the Prevention of Stroke and Dementia, John Radcliffe Hospital, University of Oxford, Oxford, UK

    Dearbhla M. Kelly

Authors
  1. Dearbhail Ni Cathain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dearbhla M. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dearbhla M. Kelly .

Editor information

Editors and Affiliations

  1. Department of Nephrology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye

    Mustafa Arıcı

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cathain, D.N., Kelly, D.M. (2023). Cerebrovascular Disease and Chronic Kidney Disease. In: Arıcı, M. (eds) Management of Chronic Kidney Disease. Springer, Cham. https://doi.org/10.1007/978-3-031-42045-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-42045-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-42044-3

  • Online ISBN: 978-3-031-42045-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation